Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stenoparib Dose Optimization in Advanced Ovarian Cancer
NCT03878849Phase 2Recruiting
- Sponsor
- Allarity Therapeutics
- Start
- Apr 2019
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of stenoparib in ovarian cancer, sponsored by Allarity Therapeutics. Primary endpoint: Evaluate the optimal dose of 2X-121 as single agent therapy at 2 years. Started Apr 2019; status: recruiting.
02
Drugs
stenoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03878849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878849.